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John G. GribbenChronic lymphocytic leukemia (CLL) remains incurable with standard therapy. Most patients with CLL have
an indolent clinical course, but it is possible to identify patients with high-risk disease. Younger patients with
adverse risk factors will die from their disease, and are therefore candidates for clinical trials exploring
hematopoietic stem cell transplantation (HSCT). Autologous SCT is feasible and has low treatment-related
mortality (TRM); but it is not curative. Myeloablative allogeneic SCT is associated with high treatment-
related mortality and, TRM few late relapses, but is applicable to only a small number of CLL patients.
The major focus of SCT in CLL has been with reduced-intensity conditioning (RIC) allogeneic SCT, which
is applicable to the more elderly patient population with this disease and which attempts to exploit the
graft-versus-leukemia (GVL) effect that exists in CLL. Steps to further decrease the morbidity and mortality
of the RIC SCT, and, in particular, to reduce the incidence of extensive chronic graft-versus-host disease
(cGVHD) remain the major focus. Many potential treatments are available for CLL, and appropriate patient
selection and the timing of SCTremain controversial and the focus of ongoing clinical trials. The use of SCT
must always be weighed against the risk of the underlying disease, particularly in a setting where improve-
ments in treatment are leading to improved outcome.
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Hematopoietic stem cell transplantation (HSCT)
is not a suitable treatment option for most patients
with chronic lymphocytic leukemia (CLL). The dis-
ease usually follows an indolent course; many patients
never require any therapy, andmost patients are too el-
derly to undergo this procedure. High-risk patients
can be identified using a number of clinical and bio-
logic features, and such younger patients are suitable
candidates for enrollment in clinical trials evaluating
the role of HSCT in CLL. The role of HSCT in a
number of other hematologic malignancies has been
established in prospective studies, but no studies in
CLL have compared the outcome after standard
chemotherapy with either autologous or allogeneic
HSCT. Using clinical and biologic features, it is pos-
sible to identify patients who are suitable candidates
for enrollment in clinical trials evaluating the role ofSt. Bartholomew’s Hospital,Institute of Cancer,Barts and
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6/j.bbmt.2008.10.022HSCT in CLL. The biggest challenges remain the de-
cision of which patients are eligible for consideration
of HSCT and when in their disease course HSCT
should be offered.Patient Selection for Stem Cell Transplantation
CLL is an extremely heterogeneous disease, with
the clinical course varying from patients who never re-
quire therapy to a rapidly progressive and fatal malig-
nancy in others. Treatment guidelines state that
therapy should be reserved for those with advanced,
symptomatic, or progressive disease [1]. There has
been significant improvement over the past decade in
the results of treatment of CLL with the use of combi-
nation chemotherapy and chemoimmunotherapy [2-6]
(Table 1). The results of the German CLL Study
Group CLL8 study, which demonstrated higher re-
sponse rates and significant improvement in progres-
sion-free survival (PFS) in patients who were treated
with rituximab in combination with fludarabine (Flu)
and cyclophosphamide (Cy), were presented at the
recent meeting of American Society of Hematology
in December 2008. In parallel with improvements in
treatment outcome, there has been dramatic progress
in the understanding of CLL pathophysiology, which
has expanded the number of useful prognostic bio-
markers including cytogenetics [7], immunoglobulin
heavy chain (IgVH) gene mutational status [8],53
Table 1. Progress in the Treatment of CLL
Study Treatment n CR% OR% PFS(months) Reference
CALGB Chlorambucil 181 4 37 14 Rai et al. [2]
9011 Fludarabine 170 20 63 20
GCLLSG Fludarabine 180 7 83 20 Eichhorst et al. [3]
CLL4 Fludarabine/Cyclophosphamide 182 24 94 48
ECOG Fludarabine 137 5 59 19
E2997 Fludarabine/Cyclophosphamide 141 23 74 32 Flinn et al. [4]
LRF Chlorambucil 366 7 72 20 Catovsky et al. [5]
CLL4 Fludarabine 181 15 80 23
Fludarabine/Cyclophosphamide 182 38 92 43
MDACC Phase II Rituximab/Fludarabine/Cyclophosphamide 224 72 95 80 Tam et al. [6]
GCLLSG Fludarabine/Cyclophosphamide 817 ? ? Significantly prolonged
inRFC arm
Hallek et al.
(unpublished observation)CLL8 (FC) ? ?
Rituximab/Fludarabine/Cyclophosphamide (RFC) patients recruited
to both arms
CR indicates complete response; OR, overall response; PFS, progression-free survival; CALGB, Cancer and Leukemia Group B; GCLLSG, German CLL
study group; ECOG, Eastern Cooperative Oncology Group; LRF, Leukemia Research Fund; MDACC, M.D. Anderson Cancer Center.
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CD38 expression [10] (Table 2). There is strong evi-
dence linking prognosis with biologic markers, but it
is not clear how we should use these factors in CLL
management.
Attempts have been made to determine which of
the risk factors in this disease are associated with suffi-
ciently poor prognosis to merit HSCT. All phase II
studies have enrolled younger patients with ‘‘high-
risk’’ disease; this term is rather loosely defined, and it
is difficult to determine precisely the risk factors used
in each of the reported studies. EuropeanBoneMarrow
Transplant (EBMT) guidelines have now been estab-
lished outlining indications for HSCT in CLL [11].
The guidelines conclude that there is evidence base
for the efficacy of allogeneic HSCT in CLL, and that
this procedure is indicated in high-risk CLL patents.
High-risk patients are defined in Table 3, and include
those requiring treatment who have p53 abnormalities
(who merit allogeneic HSCT in first response), pa-
tients who fail to achieve complete remission (CR) or
who progress within 12months after purine analogues,
those who relapse within 24 months after having
achieved a response with purine-analogue-based com-





(months) OS (months) Reference
Cytogenetics del 13p 55 92 133 Dohner et al.
2000 [7]normal 18 49 111
Trisomy 12 16 33 114
del 11q 13 13
del 17p 9 9
IgVH Mutated 47 110 300 Rassenti et al.
2004 [9]Unmutated 53 42 115
ZAP70 Negative 54 110 NS Rassenti et al.
2004 [9]Positive 46 35 NS
CD38 Negative 67 94 193 Rassenti et al.
2008 [10]Positive 33 40 109
CLL indicates chronic lymphocytic leukemia; OS, overall survival; TTT,
time to treatment.autologous HSCT, or those patients who are Flu
refractory. It should be noted that none of these cate-
gories requires assessment of biologic risk factors
except for cytogenetics for detection of p53 deletions.
Ongoing prospective clinical studies will determine
the impact of biomarkers, including IgVH mutational
status and other cytogenetic abnormalities, in identifi-
cation of patients at sufficiently high risk tomerit use of
allogeneic HSCT in first CR (CR1).Autologous HSCT
No studies have prospectively compared the role of
standard chemotherapy with autologous HSCT in
CLL, and there is no established role for this approach
except in the setting of a clinical trial. A retrospective
matched-pair analysis suggested a survival advantage
for autologous HSCT over conventional therapy
[12]. This used a risk-matched comparison between
66 patients who had undergone a uniform high-dose
therapy and autologous HSCT with a database of
291 patients treated conventionally. Matched data in-
cluded age, Binet stage, IgVH mutational status, and
lymphocyte count, and 44 patient pairs matched all 4
variables. With an overall median follow-up time of
70 and 86 months, survival was significantly longer
for the patients who had undergone autologous
HSCT compared with conventionally treated patients
when calculated from diagnosis (P5 .03) or from study
entry (P 5 .006).Table 3. EBMT Guidelines for Transplantation in CLL [11]
Allo-HSCT is a reasonable treatment option in poor-risk CLL including:
Fludarabine resistance—nonresponse or early relapse (<12 months) after
purine analogue-based therapy
Relapse <24 months after purine analogue combinations or auto-SCT
(+ high-risk genetics)
p53 mutation with treatment indication
Auto-HSCT indicated in clinical trial only.
CLL indicates chronic lymphocytic leukemia; HSCT, hematopoietic stem
cell transplantation.
Biol Blood Marrow Transplant 15:53-58, 2009 55Stem Cell Transplantation in Chronic Lymphocytic LeukemiaA number of phase II studies have reported out-
come following autologous HSCT for CLL [13-15].
These studies have demonstrated that this approach
is feasible in CLL with a treatment-related mortality
(TRM) of 1% to 10%, with most toxicity occurring
late. Among 115 previously untreated CLL patients
prospectively enrolled in a pilot study to assess the fea-
sibility of performing autologous HSCT only, 65
(56%) proceeded to transplant (14). Only 1 TRM
was seen and the CR rate after transplantation was
74% (48 of 65). The 5-year estimated overall survival
(OS) was 77.5% and PFS was 51.5%.None of the vari-
ables examined at study entry were predictive forOS or
PFS, but detectable minimal residual disease (MRD)
was highly predictive of disease recurrence. Of con-
cern, 5 of 65 (8%) patients developed posttransplant
acute myelogenous leukemia/myelodysplastic syn-
drome (AML/MDS), a complication also seen in other
series [13]. In a single-center study, among 137 pa-
tients who underwent autologous transplantation, the
1-year TRMwas 4%, but rose to 10%when late events
were taken into account. At the median follow-up time
of 6.5 years, OS was 58% after autologous HSCT.
There was no TRM among 72 patients autografted
in 5 Finnish centers with median age 57 (range: 38-
69) years and median of 32 (range: 6-181) months
from diagnosis [15]. At median follow-up of 28
months, 37% had progressed, with median OS of 95
months and PFS 48 months.
Monoclonal antibodies (mAbs) have been used to
increase the likelihood of elimination of MRD after
autologousHSCT, ex vivo [13], or by in vivo treatment
with alemtuzumab or rituximab. Alemtuzumab was
used in the conditioning regimen for autologous
HSCT in 1 arm of the German CLL Study Group
CLL3 trial, and 12 of 16 patients (87%) developed
a skin rash between 43 and 601 days post-SCT. In 7 pa-
tients biopsy confirmed graft-versus-host disease
(GVHD) persisted for a median duration was 517
(range: 60-867) days [16]. The trial was discontinued
because of the TRM, but addition of alemtuzumab
led to improved disease control. When alemtuzumab
was used at modified dose (10 mg subcutaneously 3
times per week for 6 weeks) in 34 patients who had
had a clinical response to a Flu-based regimen, the
CR rate improved from 35% to 79.5% with 56%
achieving eradication of MRD [17]. Peripheral blood
stem cell (PBSC) collection was subsequently success-
fully performed in 92%. Eighteen patients underwent
auto-HSCT, with 17 remaining in CR at a median fol-
low-up of 14.5 months post-SCT.
Most studies reported have relatively short follow-
up, and therefore focus only on TRM early postrans-
plant, but late consequences, particularly development
of secondary MDS/AML, are of concern. Among 65
previously untreated patients who were treated with
Flu followed by autologous HSCT, 8 developedMDS/AML [14], with a 5-year actuarial risk of 12%
developing MDS/AML after autologous HSCT.
Long-term follow-up reports also a high incidence of
other solid tumors in 31 (19%) patients [13]. The use
of total body irradiation (TBI) containing regimens
appears associated with increased risk of MDS/AML.Myeloablative Allogeneic HSCT
Themajor advantage of the allogeneic hSCT is the
potential for a graft-versus-leukemia (GVL) effect. Ev-
idence for a GVL effect in CLL include (1) decreased
risk of relapse in patients with chronic GVHD
(cGVHD), (2) increased risk of relapse with T cell de-
pletion, and (3) clinical responses to removal of im-
mune suppression and to donor lymphocyte infusion
(DLI) [13]. Allogeneic SCT has significant morbidity
and mortality, from regimen-related toxicity,
GVHD, and infection, but surviving patients have
long-term disease control [13,18-20]. In registry
data, TRM following allogeneic HSCT in CLL pa-
tients was 46%, with mortality from GVHD of 20%
[18]. Of 25 patients with CLL who underwent alloge-
neic hSCT at the Fred Hutchinson Cancer Center
grades ii-iv acute GVHD (aGVHD) was seen in 14 pa-
tients and 10 developed clinical extensive cGVHD and
estimated OS at 5 years was 32% [20]. Nonrelapse
mortality (NRM) at day 100 was unacceptably high
at 57% for patients conditioned with busulfan (Bu)
and cyclophosphamide (Cy) compared to 17% for pa-
tients conditioned with TBI-containing regimens.
Among 30 patients (20 related donors and 10 unrelated
donors) transplanted for CLL between 1989 and 2001
in Vancouver with a median follow-up of 4.3 years,
47% were alive in CR, both estimated OS and
disease-free survival (DFS) at 5 years were 39%. A
strong GVL effect was noted with those developing
aGVHD or cGVHD having near complete protection
from relapse.
There are no randomized studies comparing the
outcome of autologous versus allogeneicHSCT. Stud-
ies from M.D. Anderson Cancer Center demonstrate
improved outcome after allogeneic compared to autol-
ogous HSCT [21], suggesting that allogeneic HSCT
can induce durable remission even in patients with re-
fractory disease. At the Dana-Farber Cancer Institute,
162 patients with high-risk CLLwere enrolled in a ‘‘bi-
ologic randomization’’ in which 25 patients with an
HLA matched sibling donor underwent T cell-de-
pleted myeloablative allogeneic HSCT, whereas 137
with no HLA matched sibling donor underwent B
cell purged autologous HSCT, with both groups
receiving identical conditioning regimen using high-
dose Cy and TBI [13]. The 100-day TRM was 4%
after autologous or allogeneic HSCT, but later TRM
had a major impact on outcome. At the median follow-
up of 6.5 years, PFS was significantly longer following
56 Biol Blood Marrow Transplant 15:53-58, 2009J. G. Gribbenautologous than T cell-depleted allogeneic HSCT,
but no significant differences were observed in disease
recurrence or deaths without recurrence by type of
transplant. There was no difference in OS between
the 2 groups, and at the median follow-up time of
6.5 years OS was 58% after autologous and 55%
after allogeneic HSCT.
Reduced-Intensity Conditioning (RIC) HSCT
for CLL
A major advance in reducing the short-term mor-
bidity and mortality of allogeneic HSCT has been
the introduction of nonmyeloablative or RIC regimens
to allow engraftment of allogeneic stem cells. Most
patients to date have been treated on experimental
treatment protocols that allowed enrollment of many
patients with chemorefractory end-stage disease.
RIC regimens allow transplantation in older pa-
tients, making this approach more applicable to in-
creased numbers of CLL patients and results from
the larger reported studies are shown in Table 4 [22-
27]. Most patients were heavily pretreated and refrac-
tory to therapy, but despite these issues, the majority
demonstrated donor engraftment, and there was
a high CR rate. The ability of such approaches to erad-
icateMRD in patients with advancedCLL [28] and the
observation of late remissions in patients treated with
low doses of chemotherapy provide the strongest di-
rect evidence for a powerful GVL in CLL. The out-
come from the Fred Hutchinson Cancer Research
Center multi-institutional protocol after RIC alloge-
neic HSCT was recently updated for 82 patients
with advanced Flu refractory CLL using related (n 5
52) or unrelated donors (n 5 30) median age of 56
years (range: 42-72) years [22]. TRM was 23% at 5
years, with significant GVHD remaining a problem.
Five-year OS was 50% and DFS was 39%. Although
complications were higher in the patients with unre-
lated donors, there were higher CR and lower relapse















82 82 4 87% 4 63% related 25% over
(42-72) 37% unrelated
77 54 3 33% 10 81% related 18% 12m
(30-66) (0-8)
46 53 5 57% 10 33% related 17% over
(35-67) (1-10) 67% unrelated
41 54 3 27% 11 58% related 5% at 100
(37-67) (1-8) 42% unrelated 26% over
39 57 3 Not stated 90% related 2% at 100
(34-70) (2-8) 10% unrelated
30 50 3 47% 50% related 13% over
(12-63) (0-8) 50% unrelated
DLI indicates donor lymphocyte infusion, HSCT, hematopoietic stem cell trans
progression-free survival.related donors. Forty-six patients underwent RIC
transplantation at the Dana Farber Cancer Institute,
67% using unrelated donors [24]. Factors associated
with increased risk of relapse include low levels of
donor chimerism at day 30, chemorefractory disease,
increased number of previous therapies, and adverse
cytogenetics [24].
No formal assessment of RIC compared to mye-
loablative allogeneic HSCT has been undertaken,
but the outcome after RIC allogeneic SCT of 73 pa-
tients who had undergone RIC was compared with
that of 82 matched patients who had undergone stan-
dard myeloablative conditioning for CLL from the
EBMT registry database during the same time period.
Patients undergoing RIC transplants had significantly
reduced TRM, but higher relapse incidence, and there
was no significant difference in OS or PFS between
these 2 groups [29]. Of particular interest is the group
fo CLL patients with deletion of 17p and loss of p53. A
recent report from EBMT of 44 such patients suggests
that allogeneic HSCT has the potential to induce
long-term remission in these very high-risk patients
[30].
Addition of mAb to RIC SCT
GVHD remains the major concern after RIC
HSCT, and attempts have been made to utilize mAb
to reduce the incidence of GVHD without increasing
the subsequent risk fo relapse. Excellent results have
been obtained using RIC based on a combination of
Flu and Cy with the addition of rituximab at the
M.D. Anderson Cancer Center, an approach designed
to maximize GVL by early tapering of immune sup-
pression with use of rituximab and DLI. Among 39 pa-
tients treated, median age was 57 (range: 34–70) years,
median time from diagnosis to transplantation was 4.5
years [26]. All patients had recurrent advanced disease,
were heavily pretreated with a median of 3 (range: 2-8)
chemotherapy regimens and all had been previously





all 55% 49% related OS 50% 5 years Sorror et al. 2008 [22]
53% unrelated PFS 45%
34% 58% OS 72% 2 years Dreger et al. 2003 [23]
PFS 56%
all 34% 43% OS 54% 2 years Brown et al. 2006 [24]
PFS 34%
d 10% 33%* OS 51 2 years Delgado et al. 2006 [25]
all (gd 3-4) *after DLI PFS 45%
days 45% 58% OS 48% 4 years Khouri et al. 2006 [26]
PFS 44%
all 56% 21% OS 72% 2 years Schetelig et al. 2003 [27]
PFS 67%
plantation; CLL, chronic lymphocytic leukemia; OS, overall survival, PFS,
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cluding 9 (23%)with evidence of Richter’s transforma-
tion. In this series only 4 of the donors were unrelated.
Fourteen patients required immunomodulation with
rituximab and DLI for persistent disease after HSCT.
Only 1 patient died early and among the 38 evaluable
patients, 27 (71%) achieved CR, with estimated OS
at 4 years was 48% with current PFS was 44%. Grade
II-IV acute GVHD (aGVHD) was observed in 45%,
but extensive chronic GVHD (cGVHD) was reduced
without concomitant increased risk of relapse.
GVHD can also be decreased using alemtuzumab
in the conditioning regimen, but this delays post-
HSCT immune reconstitution, increases the risk of
infective complications, and does appear to impair
GVL. In 41 consecutive CLL patients treated (24
HLA-matched sibling donors and 17 unrelated volun-
teer donors, including 4 mismatched) the conditioning
regimen alemtuzumab with Flu and melphalan (Mel)
had significant antitumor effects, with 100% of pa-
tients with chemosensitive disease and 86% with che-
morefractory disease responding [25]. The TRM rate
was 26%, OS 51%, and relapse risk 29% at 2 years.
GVHD rates were relatively low, with aGVHD occur-
ring in 17 (41%) and cGVHD in 13 (33%). The unex-
pectedly high TRM rate was because of a high
incidence of fungal and viral infections.CONCLUSIONS
HSCT has a role to play in selected CLL patients,
with major focus on the use of RIC allogeneic HSCT.
Although RIC HSCT appears to result in high re-
sponse rates and eradication of PCR detectable
MRD, the follow-up of most clinical trials is too short
to assess whether HSCT can cure CLL. Future ap-
proaches to the management of this disease must
take into account the balance between the increased
morbidity andmortality of HSCT inCLLwith the cu-
rative potential that these approaches potentially offer,
in the setting of the improvements in outcome that can
now be seen using chemoimmunotherapy. In the
absence of any other treatment modalities currently
capable of improving outcome in this disease, HSCT
should be considered as a treatment approach for
younger patients with high-risk CLL early in the
course of the disease, ideally in the setting of well-de-
signed clinical trials assessing the impact of this treat-
ment on outcome in these patients. Such trials are
currently in development and will open shortly.ACKNOWLEDGMENTS
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